Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Launches Infinium® HTS-24 Arrays

Published: Thursday, October 10, 2013
Last Updated: Thursday, October 10, 2013
Bookmark and Share
Illumina’s most popular arrays will be deployed on new affordable format.

Illumina, Inc. has launched an advanced high-throughput screening (HTS) array format that significantly increases the number of samples that can be processed on the Infinium® BeadChip family of genotyping arrays.

Illumina’s Infinium assay leverages proven chemistries on a new 24-sample HTS BeadChip that supports up to 750,000 markers per sample and increases scanning capacity by up to three-fold.

“We're excited to introduce this new array format as it enables our customers to perform larger, more powerful studies that enhance discovery,” said Christian Henry, Senior Vice President and General Manager, Genomic Solutions at Illumina.

Henry continued, “The 24-sample HTS BeadChip strengthens Illumina’s leading position in the array market and further demonstrates our ability to continue innovation on our array platform, providing customers with high-quality, high-throughput genotyping solutions. The new format allows us to offer breakthrough pricing per sample which is important to enable direct-to-consumer, biobanking, basic research, and agricultural applications.”

Illumina’s HumanOmniExpress BeadChip will be the first standard array available on the 24-sample HTS BeadChip, part of a portfolio of whole-genome genotyping arrays with new affordable pricing.

This powerful array contains approximately 700,000 markers including the latest updates from the 1,000 Genomes Project strategically selected to capture the greatest amount of common SNP variation and drive the discovery of novel associations with traits and disease.

It can also include up to 50,000 custom markers, making it ideal for those interested in large genotyping studies such as core labs, genome centers, and biobanks.

“We are very happy with the quality of data we obtained using the Illumina Infinium technologies,” said Mark Kelleher, Director of Laboratory Operations at 23andMe. “We are now very excited to deploy the higher-throughput BeadChips to enhance our ability to process larger volumes of samples as we expand our customer base.”

The first consortium-designed array on the 24-sample HTS BeadChip will leverage the new format and affordable pricing to help researchers explore the association between variants to five common cancers - breast, ovarian, colon, lung, and prostate.

The Infinium OncoArray-530K BeadChip (OncoArray), designed in collaboration with leading experts from the OncoArray consortium and enabled by the development of the 24-sample HTS BeadChip, delivers the core content found on Illumina’s Infinium HumanCore array along with approximately 250,000 additional candidate variants identified by OncoArray consortium members and room for 100,000 markers of semi-custom content.

The consortium members are planning a study of unprecedented size which will use the OncoArray to analyze over 425,000 samples and detect subtle associations within and between cancer types.

“The OncoArray is a major new tool for providing future insights into the relationship between genetic variants and cancer predisposition,” said Doug Easton, Professor of Genetic Epidemiology at Strangeways Research Laboratory, University of Cambridge, and a leader of the OncoArray consortium. “It was great working with Illumina to develop the OncoArray. The array contains the custom content we need, in a high-throughput format that will make our large-scale study feasible and should lead to a whole new wave of discoveries.”

The HumanOmniExpress BeadChip is now shipping in the 24-sample HTS format. The OncoArray, iSelect, HumanCoreExome, and HumanCore BeadChips in the 24-sample HTS format are expected to begin shipping in Q1 2014.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix
LabCorp to be initial strategic partner in development of consumer applications.
Tuesday, August 18, 2015
Illumina Accelerator Invests in Second Class of Genomics Startups
Startups selected from Spain, Oregon, and California to advance breakthrough applications.
Thursday, August 06, 2015
Illumina to Acquire GenoLogics
Illumina has signed a definitive agreement to acquire GenoLogics, a developer of LIMS for life science organizations.
Wednesday, August 05, 2015
Illumina Names Sanjay Chikarmane as SVP and General Manager
Chikarmane will report to Illumina President, Francis deSouza.
Tuesday, July 21, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Biomed Realty and Illumina Announce New Build-to-Suit Laboratory Building
New building to be located in scientific research park, Granta Park, and will serve as Illumina’s new European headquarters.
Friday, June 26, 2015
Annoroad and Illumina to Co-Develop NGS Diagnostic System
Both Companies have entered into an agreement to jointly develop advanced clinical applications for reproductive health.
Thursday, June 11, 2015
Illumina, Merck KGaA and Genea Form the Global Fertility Alliance
Global fertility alliance will identify and work on improvements of fertility-related laboratory processes.
Tuesday, June 09, 2015
Illumina Files New Patent Infringement Suit
Company has filed a new suit against Ariosa Diagnostics, Inc. and Roche Molecular Systems, Inc.
Tuesday, May 19, 2015
The Agrigenomics Market
Exponential population growth and changing climate patterns are creating unique challenges for the agriculture industry. To continue to address global food needs, many researchers, breeders, and farms are turning to genomics, or DNA science, to optimize production.
Thursday, May 07, 2015
Berry Genomics NextSeq CN500 Instrument Receives CFDA Premarket Clearance
Products collaboratively developed by Berry Genomics and Illumina Serve Chinese clinical NIPT market.
Wednesday, April 01, 2015
Illumina Accelerator Secures $40 Million Boost Capital to Back New Graduates
Obtains commitment from viking global investors to advance genomics startups.
Friday, February 27, 2015
Lockheed Martin and Illumina to Collaborate
New strategic alliance to collaborate on developing genomics solutions to improve public health and wellness.
Tuesday, January 13, 2015
£15m Initiative Puts Scotland at Forefront of Gene-Led Healthcare
Initiative sees the Universities of Edinburgh and Glasgow partner with Illumina.
Monday, January 12, 2015
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!